its 12months to wait for results of the trial, however the LAD sales according to their last announcement should be beginning over the next few weeks and this will be a major price mover for the stock. I do not hold yet as I still believe their will be a little more of a retraction however their are plenty of price movers for this stock other than the cancer trial results. The following is from the announcement on 19 June.
+++++++++++++++++++++++++
Norwood Abbey Limited (ASX:NAL) has exhibited its revolutionary laser
device ("LAD") for the delivery of topically applied anaesthetics at
the 6 th International Symposium on Paediatric Pain Management. Over
400 delegates are attending the symposium in Sydney from 15-19 th
June 2003.
Norwood has received very significant interest from, Australian, New
Zealand, North American and European delegates.
"This product will revolutionize children's health care as we know
it. Imagine painless blood tests and needle procedures - children may
actually like going to the doctor" said Renee Manworren, Paediatric
Clinical Nurse and Manager of Pain Management, at the Childrens
Medical Centre of Dallas in the USA.
The Children's Medical Centre of Dallas will commence using the LAD
over the next couple of months and their response to the LAD has been
tremendous.
The LAD system consists of a laser device and single-use disposable
tip, and is intended to painlessly and temporarily alter the outer
layer of the skin (stratum corneum) enhancing the penetration of
topically applied drugs. Clinicians and nurses indicate that the slow
onset of action of topically applied anaesthetics is the major
barrier to use of these products prior to needle insertion
procedures. The LAD reduces the time of anaesthesia onset from 30-60
minutes to just 5 minutes, enabling more patients to be treated with
local anaesthetic prior to cannulation, venipuncture and other needle
sticks.
Norwood is commencing large-scale manufacture of LAD units with
Lightmed Corporation of Taiwan. Norwood expects to commence sales in
North America within weeks. Executive Chairman, Peter Hansen, said
"The Company believes that the LAD technology represents a
breakthrough in transdermal drug delivery of topically applied local
anaesthetics. According to Mr Hansen, there is also potential to use
the LAD with many other pharmaceuticals including vaccines and
anti-inflammatories.
- Forums
- ASX - By Stock
- buying opportunity
its 12months to wait for results of the trial, however the LAD...
Featured News
Add NAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online